Suppr超能文献

黏蛋白 1 和细胞外基质金属蛋白酶诱导因子是小细胞肺癌循环肿瘤细胞检测的有前途的标志物。

MUC1 and CD147 Are Promising Markers for the Detection of Circulating Tumor Cells in Small Cell Lung Cancer.

机构信息

Molecular Oncology Group, Department of Obstetrics and Gynecology, Medical University of Vienna, Vienna, Austria.

Institute of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.

出版信息

Anticancer Res. 2022 Jan;42(1):429-439. doi: 10.21873/anticanres.15501.

Abstract

BACKGROUND/AIM: Lung cancer is the most prevalent type of cancer globally and small cell lung cancer (SCLC) accounts for only 15% of all cases but exhibits a dismal prognosis. The standard of care of SCLC has not changed for decades and novel biomarkers and novel strategies for patient's care are urgently needed.

MATERIALS AND METHODS

The expression of the two potential markers MUC1 and CD147 was evaluated in circulating tumor cells (CTCs) and CTC-derived SCLC cell lines using qRT PCR, western blotting, immunohistochemistry, and ELISA assays.

RESULTS

Both CTCs enriched from patient blood samples by Parsortix isolation technology and SCLC/CTC cell lines exhibited significant expression of MUC1 and CD147. Silencing of MUC1 increased chemosensitivity of an SCLC line to topotecan.

CONCLUSION

Both markers, MUC1 and CD147, are highly expressed in patient-derived SCLC and SCLC CTC cell lines and show promise as potential biomarkers in SCLC.

摘要

背景/目的:肺癌是全球最常见的癌症类型,小细胞肺癌(SCLC)仅占所有病例的 15%,但预后较差。SCLC 的治疗标准几十年来没有改变,因此迫切需要新的生物标志物和新的患者治疗策略。

材料和方法

使用 qRT-PCR、western blot、免疫组化和 ELISA 检测循环肿瘤细胞(CTCs)和 CTC 衍生的 SCLC 细胞系中两种潜在标志物 MUC1 和 CD147 的表达。

结果

通过 Parsortix 分离技术从患者血液样本中富集的 CTCs 和 SCLC/CTC 细胞系均显示出 MUC1 和 CD147 的显著表达。沉默 MUC1 可增加 SCLC 细胞系对拓扑替康的化疗敏感性。

结论

患者来源的 SCLC 和 SCLC CTC 细胞系中均高度表达这两种标志物 MUC1 和 CD147,它们有望成为 SCLC 的潜在生物标志物。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验